Not all sufferers with CLL call for therapy. Irrespective of all recent advances, the iwCLL nevertheless recommends watchful observation for individuals with asymptomatic condition.86 This suggestion relies on not less than two randomized trials evaluating observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (